These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

746 related items for PubMed ID: 19450871

  • 1. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O'Brien PM, Li Y.
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.
    Harvey SR, Hurd TC, Markus G, Martinick MI, Penetrante RM, Tan D, Venkataraman P, DeSouza N, Sait SN, Driscoll DL, Gibbs JF.
    Clin Cancer Res; 2003 Oct 15; 9(13):4935-43. PubMed ID: 14581368
    [Abstract] [Full Text] [Related]

  • 3. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M.
    Clin Cancer Res; 2001 Jun 15; 7(6):1743-9. PubMed ID: 11410515
    [Abstract] [Full Text] [Related]

  • 4. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
    Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y.
    Gynecol Oncol; 2007 Jun 15; 105(3):695-702. PubMed ID: 17368732
    [Abstract] [Full Text] [Related]

  • 5. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, Dong JH, Li X.
    Clin Cancer Res; 2007 Jun 01; 13(11):3115-24. PubMed ID: 17545513
    [Abstract] [Full Text] [Related]

  • 6. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z, Li YF, Liu FY, Feng YL, Hou JH, Zhao MQ.
    Ai Zheng; 2007 Mar 01; 26(3):312-7. PubMed ID: 17355798
    [Abstract] [Full Text] [Related]

  • 7. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
    Chen WH, Wang C, Zhang YH, Yang YH, Zhan HY, Zhang LM.
    Zhonghua Yi Xue Za Zhi; 2007 Dec 04; 87(45):3228-32. PubMed ID: 18399120
    [Abstract] [Full Text] [Related]

  • 8. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 04; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 9. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E.
    Clin Cancer Res; 2001 Aug 04; 7(8):2396-404. PubMed ID: 11489818
    [Abstract] [Full Text] [Related]

  • 10. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q, Liang LJ, Peng BG, Zhen YY.
    Ai Zheng; 2006 Nov 04; 25(11):1433-8. PubMed ID: 17094916
    [Abstract] [Full Text] [Related]

  • 11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 04; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 12. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M.
    Urol Oncol; 2009 Jan 04; 27(2):180-6. PubMed ID: 18439850
    [Abstract] [Full Text] [Related]

  • 13. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V, Schroeder J, Kristiansen G, Roigas J, Denkert C, Johannsen M, Lein M, Loening SA, Schnorr D, Jung K, Staack A.
    Oncol Rep; 2005 Sep 04; 14(3):777-82. PubMed ID: 16077991
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer.
    Cozzi PJ, Wang J, Delprado W, Madigan MC, Fairy S, Russell PJ, Li Y.
    Hum Pathol; 2006 Nov 04; 37(11):1442-51. PubMed ID: 16949925
    [Abstract] [Full Text] [Related]

  • 15. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A.
    Oncol Rep; 2004 Oct 04; 12(4):909-13. PubMed ID: 15375521
    [Abstract] [Full Text] [Related]

  • 16. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E.
    Oncol Rep; 2011 Dec 04; 26(6):1555-60. PubMed ID: 21833477
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA.
    Clin Cancer Res; 1995 Oct 04; 1(10):1079-87. PubMed ID: 9815897
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H, Okada Y, Funahashi H, Matsuo Y, Takahashi H, Takeyama H, Manabe T.
    BMC Cell Biol; 2006 Feb 20; 7():8. PubMed ID: 16504015
    [Abstract] [Full Text] [Related]

  • 19. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J, Pilka R, Noskova V, Ehinger A, Domanski H, Andersson C, Høyer-Hansen G, Hansson SR, Casslén B.
    Mol Hum Reprod; 2004 Sep 20; 10(9):655-63. PubMed ID: 15243126
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J.
    Thromb Res; 2009 Sep 20; 123(3):537-42. PubMed ID: 18691743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.